The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. The compounds have general formula (1), wherein R.sub.1 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═0 on C.sub.1, said chain being free from —OH substituents on C.sub.3, wherein R.sub.2 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═O on C.sub.1, said chain being free from —OH substituents on C.sub.3, wherein R.sub.3 is a saturated C.sub.8-C.sub.16 aliphatic chain having a ═O on C.sub.1, said chain being free from —OH substituents on C.sub.3; wherein R.sub.4 is a hydrogen atom (H) or a phosphate group (PO.sub.4.sup.2−).

##STR00001##

The invention provides immunostimulatory glycolipids and compositions thereof and methods of use thereof.

The invention provides immunostimulatory glycolipids and compositions thereof and methods of use thereof.

The present disclosure provides compositions and methods for enhancing immune response in a subject. In an embodiment, this disclosure provides modified LPS molecules and compositions comprising the modified LPS molecules. The disclosure also provides methods for enhancing an immune response in a subject.

The present disclosure provides compositions and methods for enhancing immune response in a subject. In an embodiment, this disclosure provides modified LPS molecules and compositions comprising the modified LPS molecules. The disclosure also provides methods for enhancing an immune response in a subject.

The invention provides immunostimulatory glycolipids and compositions thereof and methods of use thereof.

The invention provides immunostimulatory glycolipids and compositions thereof and methods of use thereof.

The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula wherein R.sub.1 and R.sub.2 may be H, OH, protonated phosphate, a phosphate salt, a sugar phosphonate, or a mono-, di- or poly-saccharide, R.sub.3 may be OH or a mono-, di- or poly-saccharide, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 may be an alkyl or alkenyl chain of up to 13 carbons (for a chain of 16 carbons), and R.sub.8, R.sub.9, R.sub.10 and R.sub.11 may be H, OH, or an alkyl or alkenyl ester of up to 16 carbons, or a salt thereof.

The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula wherein R.sub.1 and R.sub.2 may be H, OH, protonated phosphate, a phosphate salt, a sugar phosphonate, or a mono-, di- or poly-saccharide, R.sub.3 may be OH or a mono-, di- or poly-saccharide, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 may be an alkyl or alkenyl chain of up to 13 carbons (for a chain of 16 carbons), and R.sub.8, R.sub.9, R.sub.10 and R.sub.11 may be H, OH, or an alkyl or alkenyl ester of up to 16 carbons, or a salt thereof.

Disclosed are cationic lipids which are compounds of Formula (I′). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

##STR00001##